




AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:


1 (currently amended). A compound where a ring structure (VIII)






representing a porphyrin, chlorin or bacteriochlorin/isobacteriochlorin ring in any of its iminonitrogen tautomeric forms carries four aromatic substituents m-hydroxy phenyl groups Ar each themselves carrying one or more hydroxy groups, one or more of which hydroxy groups is in turn linked to an antibody directed against a cell surface antigen of cancer or other diseased cells.

2 (canceled).

3 (previously presented). The compound according to claim 1 where the antibody is linked to the aromatic hydroxy group through a linking group, suitably an ether linked group particularly:-



where n is 1 to 4 and A is -OH or NH₂, or alternatively an ester-linked group particularly:-



where n and A are as before and R¹ is hydrogen or a hydrocarbon or carboxylated amino-acid side chain representing particularly glycine, alanine, lysine or glutamic acid.

4 (cancelled).

5 (currently amended). The compound according to claim 1, 2 or 3 wherein the antibody is an MAb or an antibody to an antigen as listed herein.

6 (currently amended). The compound according to claim 1, 2 or 3, where VIII represents a porphyrin .

7 (currently amended). The compound according to claim 1, 2 or 3 where VIII represents a chlorin.

8 (previously presented). The compound according to claim 7 where VIII represents m-THPC.

9 (previously presented). The compound according to claim 7, where VIII represents a chlorin other than m-THPC.

10 (currently amended). The compound according to claim 1, 2 or 3, where VIII represents a bacteriochlorin or isobacteriochlorin.

11 (withdrawn). Method of treatment of disease using an antibody conjugate according to claim 1 comprising administering said antibody conjugate to a patient in need of such treatment.

12 (cancelled).

13 (canceled)


14 (previously presented). The compound according to claim 5 wherein the antibody is mMAb 425.

15 (previously presented). The compound according to claim 6, where VIII represents m-THPP.


16 (previously presented). The compound according to claim 7, where VIII represents p-THPC or o-THPC.

17 (previously presented). The compound according to claim 10, where VIII represents m-THPB or m-THPiB.




18 (currently amended). A compound where a ring structure (VIII)



representing a porphyrin, chlorine or bacteriochlorin/isobacteriochlorin ring in any of its iminonitrogen tautomeric forms carries four aromatic substituents m-hydroxy phenyl groups Ar each themselves carrying one or more hydroxyl groups, one or more of which hydroxy groups is in turn linked to an antibody directed against a cell surface antigen of cancer or other diseased cells wherein the antibody is linked to the aromatic hydroxy group through an ether linked group:-



where n is 1 to 4 and A is -OH or NH₂, or alternatively an ester-linked group:-



where n and A are as before and R¹ is hydrogen or a hydrocarbon or carboxylated amino-acid side chain representing glycine, alanine, lysine or glutamic acid.